ADDING a medically supervised ketogenic diet improves patient survival outcomes during standard chemotherapy for pancreatic cancer. In an open-label randomized phase II screening trial, investigators evaluated the adjunctive impact of combining a medically supervised ketogenic diet with gemcitabine, nab-paclitaxel, and cisplatin in thirty-two evaluable patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Patients assigned to the intervention arm received remote continuous coaching to sustain nutritional ketosis, targeting daily blood beta-hydroxybutyrate levels between 0.5 and 3.0 millimolar through carbohydrate restriction to thirty grams or less daily. Fifteen of sixteen participants successfully achieved nutritional ketosis, maintaining target ketone concentrations for a median of nearly forty percent of treatment days. In contrast, participants in the control arm consumed their customary diet under standard nutritional counseling.
Patients adhering to the medically supervised ketogenic diet demonstrated marked extensions in clinical efficacy endpoints compared to the control group. Median progression-free survival reached 8.5 months in the ketogenic cohort versus 6.2 months among control participants, representing a forty-seven percent reduction in the risk of disease progression. Median overall survival similarly extended to 13.7 months compared to 10.2 months in the standard diet arm. Objective tumor response rates also favored the dietary group, with partial responses documented in 68.8% of patients compared to 31.2% of control participants. Serum glucose concentrations and glycated hemoglobin remained lower across therapy in the dietary cohort, whereas control patients experienced greater systemic weight gain.
The nutritional intervention demonstrated an exceptional safety profile, producing no therapy-limiting toxicities. All diet-related adverse events remained limited to mild fatigue, constipation, and transient nausea, and no patients discontinued the protocol due to dietary intolerance. Furthermore, rates of severe hematologic and gastrointestinal toxicities did not differ between the study groups, confirming that intense carbohydrate restriction does not compromise chemotherapy delivery. Global health status and functional quality of life remained stable throughout treatment. Exploratory metagenomic stool sequencing revealed substantial enrichment of beneficial gut microbes, including Akkermansia muciniphila and Intestinimonas butyriciproducens. These encouraging findings support advancement toward larger, definitive phase III trials to validate metabolic therapy in advanced oncology.
Reference
Jameson GS et al. A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. Cancer. 2026. doi:10.1002/cncr.70343.
Featured Image: Olga Miltsova on Adobe Stock.
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
